Fr1da (German General-Population T1D Screening)

What Fr1da screens for

Fr1da is a population-wide program run by Helmholtz Munich that tests young children — first in Bavaria, and since May 2026 across 12 German federal states — for the islet autoantibodies marking the immune attack behind type 1 diabetes (T1D).¹² Its defining choice is who it tests: every child at routine pediatric well-child visits, regardless of family history, rather than only relatives of people who already have T1D.¹ A single blood sample is measured for autoantibodies to insulin, GAD, IA-2, and zinc transporter 8 (ZnT8); two or more confirmed on consecutive samples define presymptomatic disease.¹

The 1/2/3 staging model

A positive result is interpreted through the consensus staging of presymptomatic T1D.³ Stage 1 is two or more islet autoantibodies with normal blood sugar; stage 2 adds dysglycemia (abnormal glucose, still no symptoms); stage 3 is clinical diabetes.³ Crossing into stage 1 confers very high lifetime risk — roughly 44% at five years and approaching 100% over a lifetime.³ Fr1da researchers refined this further with a progression-likelihood score (using IA-2 antibodies, HbA1c, and OGTT glucose) that splits stage 1 into a lower-risk substage and a higher-risk substage carrying about 46% two-year risk, comparable to stage 2.⁴

Who to screen, and predictive value

Children are screened at ages 2-10 during normal check-ups.¹ Among 220,476 children screened from 2015-2025, early-stage T1D was found in about 0.3% (stage 1, 0.23%; stage 2, 0.06%).¹ Over a median 5.7 years, the five-year progression from early stage to clinical diabetes was 36.2% (annualized 9.6%).¹ Crucially, progression was no different between children with and without a first-degree relative (P=.54) — confirming that screening limited to relatives misses most future cases, since the great majority of new T1D has no family history.¹

What early detection enables

Finding T1D before symptoms prevents the dangerous crisis of diabetic ketoacidosis (DKA) at diagnosis. In the original Fr1da cohort, only 2 of 280 screen-detected children presented in DKA — a dramatic contrast with the 25-58% who arrive in DKA when T1D is a surprise.⁵⁶ Monitoring of antibody-positive children cuts DKA at onset to as low as ~3%.⁶ Early detection also enables education, metabolic staging, longitudinal monitoring at 18 specialized diabetes centers, and access to disease-modifying trials and therapy.¹ Reassuringly, parental psychological stress, though raised at diagnosis, declined to baseline within 12 months.⁵

Reach, cost, and rescreening

Reach is the whole point: testing everyone is the only way to find the ~85-90% of future cases with no affected relative.¹ A single screen embedded in routine care is low-cost, and rescreening matters — repeat testing of 11,726 initially-negative children after ~3.3 years found 29 additional early-stage cases, nearly as often as first screening.¹

What's coming

Fr1da is moving from a Bavarian research program toward integrated standard care, and as of May 2026 it runs in 12 of Germany's 16 federal states — Bavaria, Bremen, Hamburg, Hesse, Lower Saxony, Rhineland-Palatinate and Saxony, joined that month by Berlin, Brandenburg, Mecklenburg-Western Pomerania, Saxony-Anhalt and Thuringia.²⁷ Counting the whole program since 2015, more than 240,000 children have now been tested and more than 730 found with early-stage T1D — running totals that are broader than, and should not be confused with, the 220,476-child Bavarian cohort analysed in JAMA.²¹ Fr1da's evidence directly informs the design of disease-modifying therapy trials, and the authors conclude screening "can be considered beyond genetically selected populations" — a foundation for routine childhood T1D screening internationally.¹ Remaining gaps are reimbursement, a nationwide public-health mandate, and lower-burden home collection.

References

1. Winkler C, Friedl N, Abt R, et al. Screening Children for Early-Stage Type 1 Diabetes. JAMA (2026). https://doi.org/10.1001/jama.2026.6085 ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹²

2. Helmholtz Munich. Fr1da Study Expands Early Diabetes Detection to 12 German Federal States (news release, 4 May 2026). https://www.helmholtz-munich.de/en/newsroom/news-all/artikel/fr1da-study-expands-early-diabetes-detection-to-12-german-federal-states ↩ ↩² ↩³

3. Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care (2015). https://pmc.ncbi.nlm.nih.gov/articles/PMC5321245/ ↩ ↩² ↩³

4. Weiss A, Zapardiel-Gonzalo J, Voss F, et al. Progression likelihood score identifies substages of presymptomatic type 1 diabetes in childhood public health screening. Diabetologia (2022). https://pmc.ncbi.nlm.nih.gov/articles/PMC9630406/ ↩

5. Ziegler AG, Kick K, Bonifacio E, et al. Yield of a Public Health Screening of Children for Islet Autoantibodies in Bavaria, Germany. JAMA (2020). https://pmc.ncbi.nlm.nih.gov/articles/PMC6990943/ ↩ ↩²

6. Steck AK, et al. Risk Modeling to Reduce Monitoring of an Autoantibody-Positive Population to Prevent DKA at Type 1 Diabetes Diagnosis. Diabetes Care (2023). https://pmc.ncbi.nlm.nih.gov/articles/PMC10210620/ ↩ ↩²

7. Helmholtz Zentrum München. Fr1da: Early Diagnosis and Care of Type 1 Diabetes (NCT04039945). ClinicalTrials.gov (accessed 2026). https://clinicaltrials.gov/study/NCT04039945 ↩